Omeros Releases Statement in Response to Recent False Report
June 29 2017 - 7:00AM
Business Wire
Omeros Corporation (NASDAQ: OMER) stated today that it is aware
of a report posted on-line by “Art Doyle,” an entity or group that
appears to be concealing its identity and is purportedly writing on
behalf of itself or one or more employers. “Art Doyle”
self-identifies as having a short position in Omeros’ stock. While
the company does not routinely respond to defamatory statements,
given this report’s egregious nature, the company elected to
respond. This report is replete with falsehoods, misleading
statements and incorrect analyses and conclusions. “Art Doyle”
states that it stands to profit in the event that Omeros’ share
price declines. The report is actionable and the company is
pursuing legal remedies. Omeros intends to hold all responsible
parties accountable.
Omeros accurately reports the status and results of its
commercial, clinical and development programs. The company
continues to focus on growing its sales of OMIDRIA® (phenylephrine
and ketorolac) 1%/0.3%, to advancing OMS721, its lead MASP-2
inhibitor, through Phase 3 clinical development, including
subcutaneous and intravenous formulations, and to progressing its
pipeline of additional clinical and preclinical programs.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering,
developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system. Part of its proprietary PharmacoSurgery® platform,
the company’s first drug product, OMIDRIA® (phenylephrine and
ketorolac injection) 1% / 0.3%, was broadly launched in the U.S. in
April 2015. OMIDRIA is the first and only FDA-approved drug (1) for
use during cataract surgery or intraocular lens (IOL) replacement
to maintain pupil size by preventing intraoperative miosis (pupil
constriction) and to reduce postoperative ocular pain and (2) that
contains an NSAID for intraocular use. In the European Union, the
European Commission has approved OMIDRIA for use in cataract
surgery and lens replacement procedures to maintain mydriasis
(pupil dilation), prevent miosis (pupil constriction), and to
reduce postoperative eye pain. Omeros has multiple Phase 3 and
Phase 2 clinical-stage development programs focused on:
complement-associated thrombotic microangiopathies;
complement-mediated glomerulonephropathies; Huntington’s disease
and cognitive impairment; and addictive and compulsive disorders.
In addition, Omeros has a proprietary G protein-coupled receptor
(GPCR) platform and controls 54 new GPCR drug targets and
corresponding compounds, a number of which are in preclinical
development. The company also exclusively possesses a novel
antibody-generating platform.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which are
subject to the “safe harbor” created by those sections for such
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions and variations thereof. Forward-looking statements are
based on management’s beliefs and assumptions and on information
available to management only as of the date of this press release.
Omeros’ actual results could differ materially from those
anticipated in these forward-looking statements for many reasons,
including, without limitation, risks associated with product
commercialization and commercial operations, unproven preclinical
and clinical development activities, regulatory oversight,
intellectual property claims, competitive developments, litigation,
and the risks, uncertainties and other factors described under the
heading “Risk Factors” in the company’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on May 10,
2017. Given these risks, uncertainties and other factors, you
should not place undue reliance on these forward-looking
statements, and the company assumes no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170629005503/en/
Cook Williams Communications, Inc.Jennifer Cook WilliamsInvestor
and Media Relations360.668.3701jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2024 to May 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From May 2023 to May 2024